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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYResearch in human induced pluripotent stem cells (hiPSCs) is rapidly developing and there are expectations that this research may
obviate the need to use human embryonic stem cells (hESCs), the ethics of which has been a subject of controversy for more than 15
years. In this study, we investigated approximately 3,400 original research papers that reported an experimental use of these types of hu-
man pluripotent stem cells (hPSCs) and were published from 2008 to 2013. We found that research into both cell types was conducted
independently and further expanded, accompanied by a growing intersection of both research fields. Moreover, an in-depth analysis of
papers that reported the use of both cell types indicates that hESCs are still being used as a ‘‘gold standard,’’ but in a declining proportion
of publications. Instead, the expanding research field is diversifying and hESC and hiPSC lines are increasingly being used in more inde-
pendent research and application areas.INTRODUCTION
With the first reports on generating human induced plurip-
otent stem cells (hiPSCs) from human cells (Takahashi
et al., 2007; Yu et al., 2007), the controversy regarding
the ethics of research involving human embryonic stem
cells (hESCs) (Thomson et al., 1998) has arisen once again
(Holm, 2008). Opponents of hESC research have been
quick to argue that, considering the availability of an alter-
native source of human PSCs (hPSCs), research in hESCs is
no longer needed to realize the promise of hPSCs. However,
even before the derivation of hiPSCs was first reported,
leading scientists in the field of hPSC research emphasized
the need to continue research in ESCs in case hiPSCs
became available (Hyun et al., 2007).
Several arguments have been put forward to support the
continuation or even an extension of hESC research. For
example, it has been reasoned that hESCs have advantages
over hiPSCs for regenerative therapies because the latter
may contain somatic mutations or reprogramming-
induced epigenetic defects. Indeed, there are currently 11
clinical trials registered with the FDA in which hESC-
derived cells are being used, mainly to establish treatments
for different forms of macular degeneration, but also
for neurological, cardiac, and pancreatic disorders (NIH,
clinicaltrials.gov; https://clinicaltrials.gov/). Although the
first results from one of the studies on macular degenera-
tion have been reported (Schwartz et al., 2015), the vast
majority of these trials started very recently, at a time
when hiPSCs have already been available for years.
Currently, hiPSC-derived cells are being used in one clin-914 Stem Cell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authoical trial in Japan (UMIN Clinical Trial Registry, ID
UMIN000011929; http://www.umin.ac.jp/ctr/). Another
argument in favor of continuing the use of hESCs is their
utility for basic research (e.g., to gain a better understand-
ing of human ground-state pluripotency) (Gafni et al.,
2013), for studies of early human development (Niakan
et al., 2012), or as cells that are unimpeded by epigenetic
or environmental disturbances that are likely present in
hiPSCs (e.g., to study gene function in a rather naive cell).
One of the most widely used arguments to justify hESC
research is that these cells are still needed as the ‘‘gold stan-
dard’’ for human pluripotency to characterize and qualify
hiPSC lines and gain a deeper understanding of the reprog-
ramming process. This argument is frequently used in the
political debate among stem cell researchers and propo-
nents of hESC research, and has become a central point
in the attempt to justify continued support for this
research, for example, by the European Union. Thinking
this argument through implies that research into hESCs
would mainly lead to a more complete understanding of
induced pluripotency and would become more and more
dispensable with increasing progress in hiPSC research.
Indeed, although novel and less invasive methods for re-
programming somatic cells to pluripotency have been
developed in recent years, and some difficulties in the re-
programming procedure have been overcome (Anokye-
Danso et al., 2011; Kim et al., 2009; Warren et al., 2010;
Yoshioka et al., 2013; Yu et al., 2009), many controversial
studies have reported differences between the two types
of hPSCs on both genetic and epigenetic levels (Liang
and Zhang, 2013; Ma et al., 2014) that may, for example,rs
result in deviant behaviors in specific differentiation set-
tings (Bar-Nur et al., 2011; Hu et al., 2010; Mills et al.,
2013). Thus, it is currently unequivocally crucial to use
hESCs as a reference material to gain a deeper understand-
ing of hiPSC biology and to improve reprogramming
strategies.
However, at present, the degree to which studies of
hESCs and hiPSCs overlap, whether hESCs are being
increasingly replaced by hiPSCs, and the purposes for
which hESCs are used in iPSC research remain unknown.
Six years after the onset of research into hiPSCs, scientific
projects that were planned and started after hiPSCs became
available should now be completed and published, and a
meta-analysis of the relevant papers can be performed to
indicate trends with respect to the relationship between
hESC and hiPSC research. For example, if hESC research
were just a transient technology and hESCs were mainly
used as a ‘‘gold standard’’ in hiPSC research, one would
expect the extent of independent hESC research to have
declined in recent years and the cells to be mainly used
in the context of comparative studies with hiPSCs.
In this study, we aimed to address these issues and pro-
vide a substantiated and validated database to facilitate
further discussion.We analyzed all original research papers
involving the experimental use of hPSCs that were pub-
lished after the onset of hiPSC research. This analysis
revealed that although research in hESCs and hiPSCs co-
exists, both areas are growing into independent and auton-
omous research fields that increasingly intersect. About
one-quarter of studies involving hESCs were found to
also involve hiPSCs. Furthermore, a close inspection of
the overlap of hESC and hiPSC studies showed that in
the majority of these studies, hESCs were not used as a
mere ‘‘gold standard’’ to qualify and better understand
hiPSCs, and that this role of hESCs is declining while their
use is diversifying and increasing in other areas.RESULTS
Database Searches and Paper Selection
We performed extensive searches of the PubMed database
for studies that reported an experimental use of hESCs
or hiPSCs and were published from 2008 to 2013. Our
searches resulted in 11,137 hits for hESC-related studies
and 6,291 hits for hiPSC-related studies. Of the identified
studies, we excluded 3,313 and 2,444 studies, respectively,
that were categorized by PubMed as non-original research
(e.g., comments, editorials, and reviews). In addition,
we excluded 473 hESC and 227 iPSC papers because they
appeared in journals that do not publish original experi-
mental research. To identify studies reporting original
research in hPSCs, we manually inspected abstracts and/Stemor full texts of the remaining 7,351 hESC and 3,620 hiPSC
papers for the use of hESCs and/or hiPSCs, and excluded
articles of no relevance for our analysis (e.g., studies report-
ing on research inmouse or non-humanprimate stem cells,
somatic human stem cells, or political or ethical aspects of
research).
This paper-selection procedure finally resulted in a pool
of 2,922 studies reporting on experimental use of hESCs
(38.4% of the studies inspected manually) and 1,376
studies reporting on experimental use of hiPSCs (36.2%
of studies inspected manually). These publications were
used for subsequent analyses, and the full texts of these pa-
pers were also investigated to identify the specific hESC
and/or hiPSC lines used in the studies.
Research Involving hESCs
In the course of our analysis of the 2,922 studies involving
experimental use of hESCs, we first identified papers in
which hESCs were solely used for comparison with hiPSCs
(as a ‘‘gold standard,’’ e.g., to compare novel hiPSC
lines with hESCs with respect to pluripotency marker
gene expression; see Experimental Procedures for criteria).
We identified 401 papers that used hESCs only for compar-
ative reasons and thus provided no inherent contribution
to hESC research. Therefore, these papers were excluded
from the hESC paper pool for the analyses of hESC research
trends. However, these 401 papers were included again for
the subsequent analysis of research involving both hESCs
and hiPSCs (see below).
The distribution of the remaining 2,521 (not ‘‘gold stan-
dard’’) hESC research papers on a timeline ranging from
2008 through the end of 2013 is shown in Figure 1A. To
illustrate long-term trends during the whole period of
hESC research, we also included the respective data for
the years before 2008 that were derived in a previous study
(Lo¨ser et al., 2008). Altogether, the number of hESC papers
published per year steadily increased throughout the
whole era of hESC research, with a minor decline in
2011. Although there apparently has been a slower increase
from 2010 on, the result clearly indicates a sustained high
interest in hESCs despite the worldwide availability of
hiPSCs.
We next investigated the regional distribution of hESC
research. By the end of 2013, research groups located in
38 nations reported results of experimental hESC research
in international scientific journals. To determine the
contribution of individual nations to worldwide hESC
research, we allocated each paper to a specific country ac-
cording to the affiliation of the corresponding author.
This approach is justified since about 73% of the hESC
research papers published so far resulted from national
research with scientists from only one country mentioned
in the authors list in the respective paper. The results of ourCell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authors 915
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Figure 1. Worldwide Research in hESCs
(A) Number of hESC research papers published worldwide from 2000
to 2013. Note that research papers in which hESCs were solely used
for comparison with hiPSCs (‘‘gold standard’’) were not included.
(B) Allocation of hESC research papers to individual nations ac-
cording to the affiliation of the corresponding author. Shown is the
share (in percent) of papers from a given nation in relation to the
total number of papers for the indicated period. Nations with more
than 40 original publications in the hESC field were included.analysis are presented in Figure 1B for the complete era of
hESC research (2000–2013) and for the years 2000–2009
and 2010–2013. Our results confirm the unchallenged
leadership in hESC research by groups located in the
United States, which continuously contributed about
40% of publications to international hESC research for
the past one and a half decades. The contribution of United
States-based researchers remained nearly unaltered during
the two periods shown. This is interesting because these re-
sults reflect the research output under the two fundamen-
tally different stem cell policies of the Bush and Obama
administrations (2000–2009 and 2010–2013, respectively).
In contrast to the United States, the relative contribution
to worldwide research from some other nations that
entered the hESC field very early, such as Israel, Sweden,
and Singapore, markedly declined in the second period,916 Stem Cell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authowhereas the research output from countries that entered
the hESC research field after a delay, such as Germany,
France, and Spain, increased to some degree. Notably, the
share of research from China (including Hong Kong and
Taiwan) in international hESC research increased from
less than 5% in the 2000–2009 period to more than 8%
in the second period (2010–2013). We also related the
number of hESC papers published in the 2008–2013 period
to the overall number of publications in the life and health
science fields. As shown in Figure S2A, the share of
hESC research papers in the overall publication number
slightly increased from 2008 to 2013, with some regional
differences.
To exclude distortion of this comparison, the number of
hESC research papers was related to the overall research
output of the respective country in the fields of life and
health science (Figure S2A). For example, it became
apparent that Singapore, Israel, and Finland overpropor-
tionally published research in the hESC field, whereas
there was no major imbalance toward this field in other
countries.
Research Involving hiPSCs
We next determined the extent of research involving
hiPSCs through the end of 2013. As shown in Figure 2A,
the number of papers reporting on experimental use of
hiPSCs substantially increased from 2007 (the year of the
first publication regarding hiPSCs, with only two original
research papers in the field) to 2013. We divided the hiPSC
era into two periods: 2008–2010 and 2011–2013. While
only 267 hiPSC research papers were published in the first
3 years, the number more than quadrupled to 1,109 papers
in the following 3-year period. This seems to be a usual phe-
nomenon after the establishment of a novel research field:
in the case of hESC research, the output of research even
increased more than 8-fold in the second 3-year period
of hESC research (2003–2006) compared with the first
3-year period after the first derivation of hESCs (2000–
2002). Notably, in 2013 the output from both fields of
hPSC research was at a comparable level (about 500 papers
each).
By the end of 2013, research groups from 27 nations
contributed to research into hiPSCs. As in the case of
hESCs, the leadership of US-based researchers is unchal-
lenged, with an overall share of 45% in hiPSC research pub-
lishedworldwide, although the contribution declined from
more than 50% in the 2008–2010 period to about 43%
in the more recent period (Figure 2B). As expected, when
the number of hiPSC research papers was related to the
overall publication numbers in life and health sciences
from selected countries, we observed a strong increase in
the share of hiPSC papers for all countries from 2008 to
2013 (Figure S2B). However, there are some regionalrs
AB
Figure 3. Impact of Research Papers Involving hPSCs from
Selected Countries
Average number of citations per paper and year of original research
papers involving hESCs (A) or hiPSCs (B). Papers published from
2008 to 2012 by research groups located in the indicated countries
were included in the citation analysis. Please note that studies that
involved hESCs solely for the purpose of comparison with hiPSCs
were not considered.
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Figure 2. Worldwide Research in hiPSCs
(A) Number of original research papers involving hiPSCs and pub-
lished worldwide from 2008 to 2013.
(B) Allocation of hiPSC research papers to individual nations ac-
cording to the affiliation of the corresponding author. Shown is the
share (in percent) of papers from a given nation in relation to the
total number of papers for the indicated period. Nations with more
than ten original research papers involving hiPSCs were included.differences. Although hiPSC research accounted for less
than 0.1% of research from the United States published
from 2011 to 2013, it represented more than 0.2% of
research from Israel or Singapore in the same period.
Impact of Research in hPSCs
The number of studies originating from an individual
country does not necessarily mirror the relevance of that
country’s contribution to a research field. We therefore
determined, as a measure of the impact of research, the
average frequencies with which hESC and hiPSC research
papers published from 2008 to 2012 were cited through
the end of 2013. Since reliable and comparable citation fre-
quencies are not yet available for papers published in 2013,
those papers were not included in the analysis.StemAs shown in Figure 3A, papers from the hESC research
field were cited at an average frequency of 9.1 per year,
whereas papers reporting experimental work involving
hiPSCs were citedmore frequently (19.4 citations per paper
and year). In the hESC field, research papers from the
United States, The Netherlands, and Canada were cited
more often than the average and farmore than studies orig-
inating from countries such as China, Korea, Sweden, and
Israel, confirming our previous data on the high impact of
United States-based hESC research (Lo¨ser et al., 2012).
Similarly, we found notable differences in the impact of
hiPSC research from different nations (Figure 3B). ResearchCell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authors 917
from the US, Spain, the UK, and Canada overperformed
with respect to citation frequency, whereas research papers
from other countries, such as Australia, China, and Korea,
were cited less frequently. The results are also in agreement
with our previous study and confirm the surprising finding
on an underperformance of Japanese hiPSC research with
respect to impact.
It should be noted that the high average citation num-
ber of papers from the hiPSC field is mainly due to the
high impact of early work in this field, although we did
not include pioneering work from the Yamanaka and
Thomson groups (Takahashi et al., 2007; Yu et al., 2007)
in our citation analysis. While the average citation num-
ber per year only moderately decreased for hESC research
papers published from 2008 to 2012, it sharply declined
for hiPSC papers (from 92.2 citations per year for studies
published in 2008 to 8.6 citations per year for studies pub-
lished in 2012; Figure S3A). To determine whether the
observed diversity in citation frequencies among papers
from several nations may be due to extremely frequent
citations of only a few highly popular studies, we grouped
hESC and hiPSC research papers from selected nations
according to their average citation frequency per year (Fig-
ure S3B). In the case of hESC research, the share of papers
cited at a frequency of more than 150% of the average
(15 citations per year) was more than 20% among studies
from the United States, The Netherlands, and Canada,
indicating that a rather broad range of influential hESC
papers contributed to the high citation frequency of
work from these countries. For hiPSC research, the propor-
tion of papers cited at a frequency of more than 150% of
the average (30 citations per year) is highest for work
from the United States and The Netherlands (but only
about 9%), indicating that the high average citation
frequency of hiPSC papers may be partially the result of
the high impact of an only moderate number of highly
influential papers.
Research Involving hESCs and hiPSCs
In public discussions about the tenability of using hESCs
despite the availability of hiPSCs, it is frequently reasoned
that hESCs are still needed as a gold standard for the veri-
fication and qualification of hiPSCs. Accordingly, hESC
research was predicted to be a transient technology that
would lead to a complete understanding of hiPSC charac-
teristics and would become dispensable with progress
in understanding hiPSC biology. Thus, one would expect
that (1) hiPSCs should increasingly replace hESCs; (2)
consequently, the number of studies involving hESCs
(and not hiPSCs) should decrease over time; and (3) the
majority of studies involving hESCs should also involve
hiPSCs, and hESCs should be used as a reference material
(gold standard) for purposes of comparison only.918 Stem Cell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The AuthoTo test the validity of these hypotheses, we first analyzed
the simultaneous use of hESCs and hiPSCs in experimental
research. For this purpose, we scrutinized the full texts of all
papers that reported an experimental use of hESCs and
were published in 2008–2013 for the use of hiPSCs, and
also examined the full texts of all papers that reported an
experimental use of hiPSCs and were published in the
same period for hESC utilization. The results are shown
in Figure 4A. Of the more than 3,400 original research pa-
pers involving hPSCs that were published in 2008–2013,
more than 2,000 involved the use of hESCs (but not
hiPSCs) and almost 500 papers involved the use of hiPSCs
(but not hESCs). Work reported in 890 research papers
(26.1%) was based on both types of hPSCs. As indicated
in Figure 4B, the number of papers based on either hiPSCs
only or on both hPSC types markedly increased from 2008
to 2013, whereas the number of studies that were based
solely on hESCs (but not on hiPSCs) remained stable at a
high level.
Notably, the relative share of hiPSC papers that also
involved hESCs markedly declined within the period
investigated. While nearly all hiPSC studies published in
2008 also involved hESCs (mainly for the purpose of com-
parison), this value decreased to about 55% in 2013 (Fig-
ure 4C), indicating that an increasing portion of hiPSC
research is largely independent of hESCs. This may be
partially due to the steadily growing number of papers
that report on the derivation and use of hiPSCs in the
course of establishing disease-specific cell lines, which usu-
ally do not involve ESCs. For example, we identified more
than 250 original research papers that reported on the
generation of at least one disease-specific hiPSC line.
Conversely, the portion of hESC studies that also involved
hiPSCs increased from less than 5% to more than 40% in
the same period.
Altogether, these results indicate that although the two
research fields increasingly intersect, they also exist inde-
pendently. However, while most of the hESC research pub-
lished in 2008–2013 did not involve hiPSCs, a large portion
of even recent hiPSC research still involved hESCs.
We next analyzed the intersection of 890 papers that re-
ported on experimental work in which both cell types were
utilized. Assuming that hESCs are increasingly being used
as a gold standard for hiPSC work, one would expect hESCs
to be used mainly for the purpose of comparison in these
studies. We therefore scrutinized these 890 papers for the
specific use of hESCs and categorized them into two
groups: one containing 401 papers in which hESCs were
only used for purposes of comparison (see Experimental
Proceduresfor criteria), and one containing 489 studies in
which hESCs were rather autonomous research objects.
The latter studies aimed to generate novel information
about hESCs and hiPSCs, and were usually intended tors
AB
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Figure 4. Use of hPSCs in Experimental
Research from 2008 to 2013
(A) Number of original research papers
involving hESCs, hiPSCs, or both.
(B) Number of original research papers that
were published in the indicated years and
were based on hESCs only (squares), hiPSCs
only (triangles), or both cell types (crosses).
The total numbers of research papers on
hPSCs are represented by trapezoids.
(C) Simultaneous use of hESCs and hiPSCs in
experimental research. Shown is the share of
studies (in percent) that used hiPSCs and
hESCs simultaneously in relation to the total
number of hiPSC papers (squares) and hESC
papers (triangles) published in the indicated
years. Please note that for this analysis, all
papers involving hESCs were used.gain insight into more general characteristics of hPSCs.
Other studies that clustered in this second group were pri-
marily performed with hESCs and results were just verified
in hiPSCs to generalize the findings for a second type of
hPSCs, or hiPSCs were solely used for the purpose of com-
parison. The results of this analysis with respect to time
course are presented in Figure 5. At the onset of hiPSC
research, hESCs were mainly used for mere comparison
(about 92% of papers involved both cell types and were
published in 2008). However, the share of this kind of pa-
per declined to about 35% in 2013. In contrast, studiesStembelonging to the second group formed the majority of
such papers in more recent years.
Trends in Research with hPSCs
Our data indicate that hESCs are not mainly used as the
gold standard for hiPSC research. We therefore wished to
determine what kinds of scientific questions the different
hPSC types were used to address. We roughly categorized
papers with respect to the specific use of hESCs or hiPSCs.
We restricted our analyses to the years 2011–2013 because
during this period a sufficient number of hiPSC lines wereCell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authors 919
Figure 5. Type of Use of hESCs in Studies Reporting Experi-
mental Application of Both hiPSCs and hESCs
Data are based on analysis of all papers reporting simultaneous
experimental use of hESCs and hiPSCs, and published in 2008–2013
(n = 890, 100%). The share (in percent) was determined for papers
in which hESCs were solely used for the purpose of comparison with
hiPSCs (‘‘gold standard’’ usage, triangles) or in which hESCs served
as an autonomous research object (circles). Please note that the
solid line (circles) also indicates studies in which hiPSCs played
only a minor role.available for investigating a broad range of scientific ques-
tions, whereas at the onset of hiPSC research (2008–
2010), the majority of hiPSC papers focused mainly on
the development of novel hiPSC lines.
Results of this analysis are shown in Table 1 (upper
panels). Most studies involving hESCs were directed
toward the analysis of developmental mechanisms
in humans and the development and optimization of
protocols to obtain pure populations of mature and func-
tional human cells—mainly neural, cardiac, hematopoiet-
ic, and endothelial/vascular cells. A large portion of hESC
research also aimed to analyze the cells’ specific character-
istics, for example, to identify genes expressed specifically
in these cells, to describe their genetic and epigenetic
features, or to reveal their biochemical and metabolic
peculiarities. A major part of the work was concentrated
on uncovering the molecular mechanisms of pluripo-
tency in human cells, optimizing culture protocols for
hPSCs, and developing novel methods for their reliable
characterization.
In contrast, the relative majority of work that involved
hiPSCs and was published from 2011 to 2013 aimed at
the derivation of hiPSC lines from patients with specific
diseases. In many studies, these cell lines were used as cell
models for human diseases to reveal differentiation defects
or functional deficiencies of the differentiated cells. A large
portion of theworkwas focused on optimizingmethods for
improved reprogramming and identifying human cell
types that are accessible for efficient reprogramming. In
this context, the identification of molecules and signaling
pathways involved in reprogramming was also of great in-920 Stem Cell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authoterest. Work to develop and optimize differentiation
procedures was frequently performed in conjunction
with hESCs. The determination of characteristics specific
to hiPSCs (or to hPSCs in general) and the verification of
functional characteristics of hiPSC-derived cells in animal
models of human diseases were also major topics of hiPSC
research. In contrast to hESC research, which largely de-
pended on previously derived cell lines, novel hiPSC lines
were derived in more than half of the studies published
from 2011 to 2013, indicating that there is a very large
(and steadily growing) pool of hiPSC lines in the interna-
tional research community (Soares et al., 2014).
We also wished to quantify the relative extent to which
hESCs and hiPSCs were used to address questions within
the same lines of research. Therefore, we determined the
relative share of papers in which hESCs, hiPSCs, or both
cell types were used in defined research fields, for example,
to develop and optimize differentiation protocols or to
establish diseasemodels. As shown in Table 1 (lower panel),
the vast majority of research that involved hPSCs and
sought to uncover developmental and differentiation
mechanisms in humans was done with hESCs only. Simi-
larly, work directed toward the optimization of culture
and differentiation protocols mainly involved hESCs. In
contrast, the field of disease modeling in conjunction
with the establishment of disease-specific cell lines was
clearly dominated by hiPSCs. hiPSCs and hESCs were
used to comparable extents to develop improved methods
for the genetic manipulation of hPSCs or testing of hPSC-
derived cells in animal models for human diseases.
Usage Pattern of hESC Lines in Comparative Studies
Wepreviously reported that hESC research is dominated by
only a few cell lines (Guhr et al., 2006; Lo¨ser et al., 2010)
and that patterns of hESC line usage can be easily modeled
as a cumulative advantage process (Schuldt et al., 2013).
Others have proposed a policy-driven model to explain
the preferential use of only a few hESC lines (Scott et al.,
2009). Thus, we were interested in determining which
hESC lines were the most frequently used for comparison
with hiPSCs. To that end, we analyzed the 401 papers
(‘‘gold standard’’) in which hESCs were used solely for the
purpose of comparison. We found that 372 of these papers
contained information about the specific hESC line(s)
used. The results of our analysis are given in Table 2.
Notably, in more than half of the papers (57.4%), the
hESC H9 line was used for comparison, followed by the
H1 line (29.8%), and frequently both lines were used in
the same study. Altogether, the five oldest hESC lines
(H1, H7, H9, H13, and H14), which were derived at WiCell
as early as 1998 (Thomson et al., 1998), were used as the
benchmark in about 74% of the studies to assess the integ-
rity and characteristics of hiPSCs. The use especially of cellrs
Table 1. Topics of Research Involving hESCs and hiPSCs and Published from 2011 to 2013
hESC Papers (2011–2013)a
Topicb Paper Number % of Papers
Development/optimization of differentiation protocols 387 26.7
Analysis of molecular mechanisms of development 355 24.4
Analysis of molecular characteristics of hESCs 209 14.4
Investigation of the molecular basis of pluripotency 148 10.2
Optimization of culture conditions/characterization methods 132 9.1
Provision of differentiated human cells for cell research 93 6.4
Use of hESC-derived cells in animal models of human diseases 70 4.8
Cell models for drug development/toxicity testing 54 3.7
Disease modeling 30 2.1
Development/optimization of methods for genetic manipulation 24 1.7
Derivation of novel hESC lines 48 3.3
hiPSC Papers (2011–2013)
Topicb Paper Number % of Papers
Generation of disease-specific cell lines 227 20.5
Disease modeling 189 17.0
Development/optimization of differentiation protocols 161 14.5
Development/optimization of methods for reprogramming 150 13.5
Analysis of molecular characteristics of hiPSCs 116 10.5
Molecular mechanisms of development 81 7.3
Molecular basis of reprogramming 71 6.4
Use of hiPSC-derived cells in animal models of human diseases 61 5.5
Optimization of culture conditions/characterization methods 61 5.5
Cell models for drug development/toxicity testing 32 2.9
Development/optimization of methods for genetic manipulation 22 2.0
Derivation of novel hiPSC lines 562 50.7
Research Papers Involving Any Type of hPSCs (2011–2013)
Topicb Paper Number hESC (%) hiPSC (%) Both (%)
Development/optimization of differentiation protocols 465 65.4 16.8 17.8
Analysis of molecular mechanisms of development 398 79.6 10.8 9.5
Generation of disease-specific cell lines/disease modeling 277 11.6 85.2 3.2
Optimization of culture conditions/characterization methods 156 60.9 15.4 23.7
Use of hPSC-derived cells in animal models for human diseases 133 46.6 47.4 6.0
Drug development/toxicity testing 81 60.5 33.3 6.2
Development/optimization of methods for genetic manipulation 36 38.9 33.3 27.8
aStudies in which hESCs were used for mere comparison with hiPSCs were not considered.
bSeveral topics can be the subject of the same paper.
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Table 2. Use of hESC Lines for the Sole Purpose of Comparison
in hiPSC Research: 2008–2013
hESC
Linea
Year of
Publication Provider
Use in
Comparative
Research
(% of Studies)b
Use in Overall
Research
(% of Studies)b
H9 1998 WiCell 57.4 47.1
H1 1998 WiCell 29.8 24.5
H7 1998 WiCell 7.2 8.0
HES-3 2000 ES Cell
International
4.8 6.5
KhES-1 2006 Kyoto
University
4.8 3.1
KhES-3 2006 Kyoto
University
4.6 2.5
HUES6 2004 Harvard
University
4.0 1.7
HUES9 2004 Harvard
University
3.8 4.3
BG01 2001 BresaGen 3.5 4.9
HES-2 2000 ES Cell
International
2.9 4.5
H14 1998 WiCell 2.9 2.2
aSublines are grouped with the parental hESC line.
bNote that in a subsection of papers, more than one hESC line was used.line H9 was significantly higher in comparative studies
than in overall hESC research.DISCUSSION
To identify global trends in the application of hESCs and
hiPSCs in research, we established a curated database of
published primary research conducted with these cells be-
tween 2008 and 2013, and performed a thorough analysis
of studies involving only hESCs or only hiPSCs, as well as
intersecting research. The results show that both the hESC
and hiPSC research fields increased (hiPSC) or remained at
a high level (hESC) with respect to impact and quantita-
tive paper output. Research in which both hPSC types
were applied in similar proportions included the develop-
ment and optimization of cultivation and differentiation
protocols, and research on animal models to develop
cell-based therapies. Interestingly, we identified early
segregation trends for the preferential research use of
hESCs and hiPSCs in the recent past. For example, trends
for the use of mostly hESCs include basic research on cell
pluripotency and plasticity, and analysis of (early) devel-922 Stem Cell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authoopmental mechanisms. hiPSCs, on the other hand, clearly
dominate the field of disease modeling, frequently in
conjunction with the derivation of novel disease-specific
hiPSC lines and the correction of genetic defects in vitro.
Other topics of hiPSC research included the provision of
cell models for drug development and toxicity testing,
although rather surprisingly, a slight relative overweight
of hESCs was found in this application field. This finding
may have been influenced by our strict inclusion criteria,
which only considered studies that directly used hPSCs,
and excluded about 80 studies in which only commer-
cially available hPSC-derived cardiomyocytes, hepato-
cytes, or neural cells were used. We also excluded other
secondary studies that used hPSC-derived nucleic acids,
proteins, or data. However, a more likely explanation is
the relatively short time span of the research used in
this analysis (years 2011–2013). Follow-up studies will be
required to establish a trend in this specific area, especially
in light of the recent establishment of large-scale hiPSC
banking projects to meet the anticipated demand in this
field (McKernan and Watt, 2013). It is intriguing that
about 20% of the studies involving hiPSCs were focused
on the establishment of disease-specific human cell lines,
and frequently provided for the first time relevant human
cell models for poorly understood, rare, and fatal human
diseases (Cherry and Daley, 2013; Peitz et al., 2013).
Notably, a large number of projects that aim to derive
novel disease-specific hiPSC lines are currently registered
with the NIH (ClinicalTrials.gov). While hESCs are a valu-
able resource for generating isogenic variants for specific
diseases on a naive background, and therefore are also
playing an increasing role in disease modeling, banking
projects involving hESCs are mostly directed toward the
distribution of highly characterized lines for comparable
basic research and prospective clinical applications (Stacey
et al., 2013). Moreover, in many cases, hESCs are used to
provide a reliable source for differentiated or progenitor
human cells such as neurons and cardiomyocytes, which
are not readily accessible in other ways.
The trend for increased differentiation in the field is par-
alleled by a large and increasing proportion of papers in
which both cell types are being used. To analyze the valid-
ity of the ‘‘gold standard’’ argument that is frequently
used to justify the continued use of hESCs in research,
we analyzed the intersection of research papers in which
both cell types were applied for their specific uses.
Although such intersecting research is increasing in abso-
lute numbers, it includes only a minority (about 26%) of
all papers involving hPSCs. Moreover, only a portion of
these papers used hESCs solely as a gold standard for
comparative research. In addition, the overall proportion
of hiPSC studies that also use hESCs is steadily declining,
likely because the ‘‘gold standard’’ aspect is less relevant if,rs
for example, the research is focused on disease models or
on differentiated progeny derived from hiPSCs. In the
same period in which the proportion of hiPSC work
involving hESCs declined, the number of hESC-only pa-
pers did not decline. These findings may indicate that
the trend of field diversification and specification is at
least partially due to the specific and differential applica-
bility of these two cell types. These findings also show
that hESCs are indeed useful as a gold standard and in
general for standardization and benchmarking efforts in
the field, but that this is not the major justification for
their continued high level of use in research. In addition,
the use of hESCs for standardization and comparative
research is limited to a very small number of cell lines,
which are already well characterized and available from
established hESC banks. Hence, it appears that the ‘‘gold
standard’’ itself is restricted to a small set: most studies
used only a single hESC benchmark line (e.g., H9) rather
than a larger, representative panel. The lack of generally
accepted standard hPSC lines and insufficient knowledge
about acceptable phenotypic tolerances may partly
explain this restriction to the most commonly used lines
and their quasi-standard status (Adewumi et al., 2007;
Boulting et al., 2011; Loring and Rao, 2006; Martı´ et al.,
2013; Nestor et al., 2013). The large hiPSC banks that
are currently being established may help to define such
benchmark standards.
In the controversial field of pluripotent stem cell
research, it is vital to argue on the basis of reliable and solid
data that best reflect the actual research situation and are
carefully validated. However, available data on recent
research activities in this field are often based on abstract
searches and automatized algorithms, and not on manu-
ally verified data bank searches. For example, Pera and
Trounson (2013) estimated the number of publications
on hESC research to be nearly 2,000 per year for 2010
through 2012, since review articles were included in their
data pool (Pera and Trounson, 2013). More strikingly, the
recent European Union-funded Stem Cell Report, pub-
lished in collaboration with Elsevier and Kyoto University
(Barfoot et al., 2013), claimed that more than 500 papers
on hESCs were published in 2008, and stated that in
2012, researchers from Germany published substantially
more papers in the hESC field than groups from Japan,
Korea, or Israel. However, a closer inspection of the data
set used for this extensive and highly appreciated study
revealed that, for example, the German hESC paper pool
contained many publications in which hESCs were not
used. Abstract statements such as ‘‘Despite their potential
benefits, ethical and practical considerations limit the
application of NSCs derived from hESCs or adult brain
tissue. Thus, alternative sources are required’’ resulted in
consideration of the respective paper as a contribution toStemhESC research. Altogether, nearly 50% of the alleged
hESC papers from Germany used for this database did not
report any research involving hESCs. Moreover, while our
study was under review, Alberta et al. (2015) published an
analysis assessing the impact of stem cell research funding
programs in selected U.S. states. These authors searched the
Web of Science for articles that contained the phrase ‘‘hu-
man embryonic stem cell’’ in the title, abstract, or key
words, and were (co-)produced by authors with an affilia-
tion in the United States. However, our analysis of this
data pool (1,544 hESC-related papers fromU.S. authors) re-
vealed that more than 15% of the studies identified by
Alberta et al. are not relevant because they did not report
research involving hESCs. On the other hand, more than
550 relevant papers from the United States that involved
hESCs and are present in our database were missed
(including the one by Thomson et al. [1998]). The vast
reduction of the initially high number of papers obtained
through our selection process confirms that it may be
essential for the assessment of research activities to initially
generate broader publication-based data pools, and to
manually validate each included paper. An analysis of
papers only on the basis of meta-data provided by a search
engine may result in a massive over- or underestimation of
research output and may lead to misleading conclusions,
which could potentially influence and misdirect political
decision-making.
When compared with our previous studies (Guhr et al.,
2006; Lo¨ser et al., 2008, 2010, 2012), the current analysis
revealed some relevant changes in the number and ranking
of countries involved in hESC research. In addition, we
substantiated that a country’s quantitative output of papers
in hPSC research does not necessarily correlate with the
impact of this research. For example, our previous surpris-
ing finding that Japan is somewhat underperforming in
the hiPSC field was confirmed for recent years with respect
to impact per study. Moreover, although the number of
hPSC research papers from China increased markedly
over the past years, research from China clearly underper-
formed with respect to impact per study in both the
hESC and hiPSC fields. However, it may be expected that
this situation will change in the near future as Chinese
research groups increasingly publish papers in highly influ-
ential, ranking international journals.
Our present study was based on a pool of stem cell pub-
lications that only included original research papers. It is
a well-reasoned assumption that aspects concerning stem
cell history, the prospect of using pluripotent stem cells
in future therapies, and the ethical and legal aspects of
research cannot reflect the extent of research activities in
this field, and their inclusion in such an analysis is irrele-
vant. Our data on the extent of experimental research
involving hPSCs show that both hESCs and hiPSCs supplyCell Reports j Vol. 4 j 914–925 j May 12, 2015 j ª2015 The Authors 923
a vital research field that has not yet reached maturity. The
emerging trends of differentiation, diversification, and
fusionwith other research and technological fields indicate
that both hESCs and hiPSCs will be essential and indepen-
dent components of this research area.EXPERIMENTAL PROCEDURES
Paper pools were established by searches of the PubMed database,
which is accessible through the NIH National Library of Medicine
(NIH/NLM). Data bank searches were performed separately to
identify hESC- and hiPSC-related publications using the search
strings described earlier (Guhr et al., 2006; Mu¨ller et al., 2010)
and modified as indicated in Supplemental Experimental Proce-
dures. The complete procedures used to identify research papers
with relevance for our analysis are described in the Supplemental
Information and outlined schematically in Figure S1. Briefly,
initial searches of the database resulted in about 17,400 hits
(11,137 for hESC-related papers and 6,291 for hiPSC-related pa-
pers). We excluded articles that were categorized by PubMed as
non-research papers, as well as studies that appeared in journals
that do not publish original experimental research. Abstracts
and/or full texts of the remaining 11,000 papers were inspected
manually for the use of hESCs or hiPSCs before they were added to
the paper repositories. Therefore, our paper pools only contain
original research papers in which hESCs and/or hiPSCs were
used experimentally.
To identify papers in which hESCs were merely used as a gold
standard for iPSCs, we determined whether hESCs were solely
used (1) to determine whether newly derived hiPSCs showed
typical characteristics of hPSCs (usually with respect to cell
morphology, presence of pluripotency-associated gene products,
mRNA andmiRNA gene-expression patterns, and/or DNAmethyl-
ation patterns), (2) to verify that protocols developed for culture
and differentiation of hiPSCs would also be applicable to hESCs,
or (3) to investigate whether molecular characteristics initially
identified in hiPSCs could also be found in hESCs. If hESCs were
used for only these comparative purposes, the usage was assigned
a ‘‘gold standard’’ application. These studies are not considered as
original research in hESCs, and consequently the papers were not
included in the analyses of hESC research.
Allocation of a paper to a country was done according to the cor-
responding author’s affiliation. Citation analysis was performed as
described previously (Lo¨ser et al., 2012) using the Scopus database.
Details are given in Supplemental Experimental Procedures.
Categorization of papers into topic groups was performed by
manual inspection of abstracts/full texts, since the use of keywords
assigned by the publisher and provided by the PubMed and Scopus
databases turned out to be an unreliable tool for grouping papers
into scientific categories.SUPPLEMENTAL INFORMATION
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